1. Search Result
Search Result
Results for "

PSD-95

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

9

Peptides

3

Recombinant Proteins

4

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2307

    iGluR NO Synthase Neurological Disease
    Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
    Tat-NR2Baa
  • HY-P0117
    Tat-NR2B9c
    Maximum Cited Publications
    8 Publications Verification

    Tat-NR2Bct; NA-1

    iGluR NO Synthase Neurological Disease
    Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .
    Tat-NR2B9c
  • HY-P0117A
    Tat-NR2B9c TFA
    Maximum Cited Publications
    8 Publications Verification

    Tat-NR2Bct TFA; NA-1 TFA

    iGluR NO Synthase Neurological Disease
    Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .
    Tat-NR2B9c TFA
  • HY-100457
    IC87201
    2 Publications Verification

    iGluR Neurological Disease
    IC87201, an inhibitor of PSD95-nNOS protein-protein interactions, suppresses NMDAR-dependent NO and cGMP formation.
    IC87201
  • HY-W009118

    Amino Acid Derivatives Others
    Fmoc-5-Ava-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize fatty acid-based dimeric peptides with PSD-95 inhibitory activity .
    Fmoc-5-Ava-OH
  • HY-RS22138

    Dlgh4; PSD95; SAP90; PSD-95; SAP90A

    Small Interfering RNA (siRNA) Others

    Dlg4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dlg4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dlg4 Mouse Pre-designed siRNA Set A
    Dlg4 Mouse Pre-designed siRNA Set A
  • HY-RS28659

    Dlgh4; PSD95; Sap90

    Small Interfering RNA (siRNA) Others
    Dlg4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dlg4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Dlg4 Rat Pre-designed siRNA Set A
    Dlg4 Rat Pre-designed siRNA Set A
  • HY-RS03799

    MRD62; PSD95; SAP90; SAP-90

    Small Interfering RNA (siRNA) Others

    DLG4 Human Pre-designed siRNA Set A contains three designed siRNAs for DLG4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DLG4 Human Pre-designed siRNA Set A
    DLG4 Human Pre-designed siRNA Set A
  • HY-P10212

    UCCB01-125

    iGluR Neurological Disease
    AVLX-125 (UCCB01-125) is a PSD-95 and PDZ domain inhibitor with Kd value of 10 nM. AVLX-125 can be used in the study of inflammatory pain .
    AVLX-125
  • HY-P2307A

    iGluR NO Synthase Neurological Disease
    Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
    Tat-NR2Baa TFA
  • HY-155355

    iGluR Neurological Disease
    LY836 is an orally active neuroprotective agent. LY836 significantly blocks PSD95-nNOS association in cortical neurons. LY836 can be used in study ischemic stroke .
    LY836
  • HY-P1195

    iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-P1195A

    iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide TFA
  • HY-P10401

    Apoptosis iGluR Cardiovascular Disease Neurological Disease
    TAT-GluR6-9c is a GluR6-PSD95 interaction blocker. By regulating the GluR6 mediated signaling pathway, TAT-GluR6-9c inhibits the activation of JNK and phosphorylation of c-Jun, reduces the expression of Fas L and thus reduces the occurrence of apoptosis. TAT-GluR6-9c can be used to study cerebral ischemia and neuroprotective strategies .
    TAT-GluR6-9c
  • HY-117772

    iGluR Metabolic Disease Inflammation/Immunology
    FSC231 is a PSD‐95/DLG/ZO‐1 (PDZ) domain inhibitor of PICK1. FSC231 has analgesic effects .
    FSC231
  • HY-100456

    iGluR Neurological Disease
    ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.
    ZL006

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: